Nucleic Acids Research, 2002, Vol. 30, No. 20 4460-4469
© 2002 Oxford University Press
‘Immunomers’—novel 3'–3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents
Hybridon, Inc., 345 Vassar Street, Cambridge, MA 02139, USA
*To whom correspondence should be addressed. Tel: +1 617 679 5501; Fax: +1 617 679 5582; Email: sagrawal{at}hybridon.com
Oligodeoxyribonucleotides containing CpG dinucleotides (CpG DNAs) are currently being evaluated as novel immunomodulators in clinical trials. Recently, we showed that an accessible 5' end is required for immunostimulatory activity and blocking the 5' end of CpG DNA by conjugation of certain ligands abrogates immunostimulatory activity. Based on these results, we designed and synthesized 3'–3'-linked CpG DNAs that contained two or more identical CpG DNA segments, referred to here as ‘immunomers’. The use of solid support bearing diDMT-glyceryl-linker permitted convenient synthesis of immunomers with both segments synthesized simultaneously, giving better yields and purity. The in vitro and in vivo studies suggest that as a result of accessibility to two 5' ends for recognition, immunomers show an enhanced immunostimulatory activity compared with linear CpG DNAs. We also studied the suitability of a number of different linkers for attaching the two segments of immunomers. A C3-linker was found to be optimal for joining the two segments of immunomers. Incorporation of multiple linkers between the two segments of immunomers resulted in different cytokine profiles depending on the nature and number of linkers incorporated. Additionally, the length of immunomer also plays a significant role in inducing immune responses. An immunomer containing 11 nt in each segment showed the highest activity and an 11mer linear CpG DNA failed to stimulate an immune response. These results suggest that immunomers have several advantages over conventional linear CpG DNAs for immunomodulatory activity studies.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Yu, M. R. Putta, L. Bhagat, M. Dai, D. Wang, A. F. Trombino, T. Sullivan, E. R. Kandimalla, and S. Agrawal Impact of Secondary Structure of Toll-Like Receptor 9 Agonists on Interferon Alpha Induction Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4320 - 4325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Lan, E. R. Kandimalla, D. Yu, L. Bhagat, Y. Li, D. Wang, F. Zhu, J. X. Tang, M. R. Putta, Y. Cong, et al. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8 PNAS, August 21, 2007; 104(34): 13750 - 13755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Damiano, R. Caputo, S. Garofalo, R. Bianco, R. Rosa, G. Merola, T. Gelardi, L. Racioppi, G. Fontanini, S. De Placido, et al. TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts PNAS, July 24, 2007; 104(30): 12468 - 12473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wang, E. R. Rayburn, W. Wang, E. R. Kandimalla, S. Agrawal, and R. Zhang Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol. Cancer Ther., August 1, 2006; 5(8): 2106 - 2114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Putta, F. Zhu, Y. Li, L. Bhagat, Y. Cong, E. R. Kandimalla, and S. Agrawal Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications Nucleic Acids Res., June 23, 2006; 34(11): 3231 - 3238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wang, E. R. Rayburn, W. Wang, E. R. Kandimalla, S. Agrawal, and R. Zhang Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol. Cancer Ther., June 1, 2006; 5(6): 1585 - 1592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Damiano, R. Caputo, R. Bianco, F. P. D'Armiento, A. Leonardi, S. De Placido, A. R. Bianco, S. Agrawal, F. Ciardiello, and G. Tortora Novel Toll-Like Receptor 9 Agonist Induces Epidermal Growth Factor Receptor (EGFR) Inhibition and Synergistic Antitumor Activity with EGFR Inhibitors Clin. Cancer Res., January 15, 2006; 12(2): 577 - 583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Nesterova, N. R. Johnson, T. Stewart, S. Abrams, and Y. S. Cho-Chung CpG Immunomer DNA Enhances Antisense Protein Kinase A RI{alpha} Inhibition of Multidrug-Resistant Colon Carcinoma Growth in Nude Mice: Molecular Basis for Combinatorial Therapy Clin. Cancer Res., August 15, 2005; 11(16): 5950 - 5955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Kandimalla, L. Bhagat, Y. Li, D. Yu, D. Wang, Y.-P. Cong, S. S. Song, J. X. Tang, T. Sullivan, and S. Agrawal Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent Toll-like receptor 9 agonists PNAS, May 10, 2005; 102(19): 6925 - 6930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Kandimalla, L. Bhagat, F.-G. Zhu, D. Yu, Y.-P. Cong, D. Wang, J. X. Tang, J.-Y. Tang, C. F. Knetter, E. Lien, et al. A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif PNAS, November 25, 2003; 100(24): 14303 - 14308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Marshall, E. M. Hessel, J. Gregorio, C. Abbate, P. Yee, M. Chu, G. V. Nest, R. L. Coffman, and K. L. Fearon Novel chimeric immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cells Nucleic Acids Res., September 1, 2003; 31(17): 5122 - 5133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Kandimalla, L. Bhagat, D. Wang, D. Yu, F.-G. Zhu, J. Tang, H. Wang, P. Huang, R. Zhang, and S. Agrawal Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles Nucleic Acids Res., May 1, 2003; 31(9): 2393 - 2400. [Abstract] [Full Text] [PDF]
|
|